Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles

Neoplasia

Volumn 10, Issue 3, 2008, Pages 223-234

  Spänkuch, Birgit ^a,b   Steinhauser, Isabel ^b   Wartlick, Heidrun ^b   Kurunci Csacsko, Elisabeth ^a   Strebhardt, Klaus I ^a   Langer, Klaus ^b  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; CASPASE 7; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN SERUM ALBUMIN; MESSENGER RNA; NANOPARTICLE; POLO LIKE KINASE 1; TRASTUZUMAB;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 40149097015     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07916     Document Type: Article

References (50)

1. L Brannon-Peppas JO Blanchette Nanoparticle and targeted systems for cancer therapy Adv Drug Deliv Rev 56 2004 1649 1659
2. D Schrama RA Reisfeld JC Becker Antibody targeted drugs as cancer therapeutics Nat Rev Drug Discov 5 2006 147 159
3. DB Kirpotin DC Drummond Y Shao MR Shalaby K Hong UB Nielsen JD Marks CC Benz JW Park Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res 66 2006 6732 6740
4. FA Barr HH Sillje EA Nigg Polo-like kinases and the orchestration of cell division Nat Rev Mol Cell Biol 5 2004 429 440
5. K Strebhardt A Ullrich Targeting polo-like kinase 1 for cancer therapy Nat Rev Cancer 6 2006 321 330
6. MR Smith ML Wilson R Hamanaka D Chase H Kung DL Longo DK Ferris Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase Biochem Biophys Res Commun 234 1997 397 405
7. K Ando T Ozaki H Yamamoto K Furuya M Hosoda S Hayashi M Fukuzawa A Nakagawara Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation J Biol Chem 279 2004 25549 25561
8. VA Smits R Klompmaker L Arnaud G Rijksen EA Nigg RH Medema Polo-like kinase-1 is a target of the DNA damage checkpoint Nat Cell Biol 2 2000 672 676
9. B Spankuch-Schmitt J Bereiter-Hahn M Kaufmann K Strebhardt Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells J Natl Cancer Inst 94 2002 1863 1877
10. B Spankuch-Schmitt G Wolf C Solbach S Loibl R Knecht M Stegmuller G von Minckwitz M Kaufmann K Strebhardt Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells Oncogene 21 2002 3162 3171
11. B Spankuch Y Matthess R Knecht B Zimmer M Kaufmann K Strebhardt Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1 J Natl Cancer Inst 96 2004 862 872
12. X Liu RL Erikson Polo-like kinase (Plk) 1 depletion induces apoptosis in cancer cells Proc Natl Acad Sci USA 100 2003 5789 5794
13. HA Lane EA Nigg Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes J Cell Biol 135 1996 1701 1713
14. JP Cogswell CE Brown JE Bisi SD Neill Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function Cell Growth Differ 11 2000 615 623
15. X Liu M Lei RL Erikson Normal cells, but not cancer cells, survive severe Plk1 depletion Mol Cell Biol 26 2006 2093 2108
16. ME Gleave BP Monia Antisense therapy for cancer Nat Rev Cancer 5 2005 468 479
17. TL Jason J Koropatnick RW Berg Toxicology of antisense therapeutics Toxicol Appl Pharmacol 201 2004 66 83
18. C Zhang J Pei D Kumar I Sakabe HE Boudreau PC Gokhale UN Kasid Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles Methods Mol Biol 361 2007 163 185
19. D Li H Yu H Huang F Shen X Wu J Li J Wang X Cao Q Wang G Tang FGF receptor-mediated gene delivery using ligands coupled to polyethylenimine J Biomater Appl 22 2007 163 180
20. ®) coupled nanoparticles Int J Pharm 331 2007 190 196
21. ME Hayes DC Drummond K Hong WW Zheng VA Khorosheva JA Cohen CO Noble VI JW Park JD Marks CC Benz Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation Mol Pharm 3 2006 726 736
22. R Nahta FJ Esteva HER-2-targeted therapy: lessons learned and future directions Clin Cancer Res 9 2003 5078 5084
23. H Wartlick K Michaelis S Balthasar K Strebhardt J Kreuter K Langer Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells J Drug Target 12 2004 461 471
24. ®) on three treatment schedules in patients with solid tumors Cancer Chemother Pharmacol 60 2007 759 766
25. A Sparreboom CD Scripture V Trieu PJ Williams T De A Yang B Beals WD Figg M Hawkins N Desai Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol) Clin Cancer Res 11 2005 4136 4143
26. K Langer C Kumar Peptide nanoparticles Biological and Pharmaceutical Nanomaterials Weinheim 2006 Wiley-VCH Germany 145 184
27. SM Moghimi AC Hunter JC Murray Nanomedicine: current status and future prospects FASEB J 19 2005 311 330
28. A Arnedo S Espuelas JM Irache Albumin nanoparticles as carriers for a phosphodiester oligonucleotide Int J Pharm 244 2002 59 72
29. B Spankuch S Heim E Kurunci-Csacsko C Lindenau J Yuan M Kaufmann K Strebhardt Down-regulation of polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo Cancer Res 66 2006 5836 5846
30. H Wartlick B Spankuch-Schmitt K Strebhardt J Kreuter K Langer Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles J Control Release 96 2004 483 495
31. I Steinhauser B Spankuch K Strebhardt K Langer Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells Biomaterials 27 2006 4975 4983
32. X Chen TK Yeung Z Wang Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3 Biochem Biophys Res Commun 277 2000 757 763
33. W Lin MC Garnett E Schacht SS Davis L Illum Preparation and in vitro characterization of HSA-mPEG nanoparticles Int J Pharm 189 1999 161 170
34. B Spankuch E Kurunci-Csacsko M Kaufmann K Strebhardt Rational combinations of siRNAs targeting Plk1 with breast cancer drugs Oncogene 26 2007 5793 5807
35. JK Vasir V Labhasetwar Targeted drug delivery in cancer therapy Technol Cancer Res Treat 4 2005 363 374
36. H Maeda J Wu T Sawa Y Matsumura K Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J Control Release 65 2000 271 284
37. SD Li L Huang Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells Mol Pharm 3 2006 579 588
38. TM Allen Ligand-targeted therapeutics in anticancer therapy Nat Rev Cancer 2 2002 750 763
39. RM Schiffelers A Ansari J Xu Q Zhou Q Tang G Storm G Molema PY Lu PV Scaria MC Woodle Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res 32 2004 e149
40. L Zhang S Hou S Mao D Wei X Song Y Lu Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells Int J Pharm 287 2004 155 162
41. A Jemal R Siegel E Ward T Murray J Xu C Smigal MJ Thun Cancer statistics, 2006 CA Cancer J Clin 56 2006 106 130
42. P Lenart M Petronczki M Steegmaier FB Di JJ Lipp M Hoffmann WJ Rettig N Kraut JM Peters The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 Curr Biol 17 2007 304 315
43. M Steegmaier M Hoffmann A Baum P Lenart M Petronczki M Krssak U Gurtler P Garin-Chesa S Lieb J Quant BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo Curr Biol 17 2007 316 322
44. TJ Lansing RT McConnell DR Duckett GM Spehar VB Knick DF Hassler N Noro M Furuta KA Emmitte TM Gilmer In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 Mol Cancer Ther 6 2007 450 459
45. M Schmidt HP Hofmann K Sanders G Sczakiel TL Beckers V Gekeler Molecular alterations after polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells Mol Cancer Ther 5 2006 809 817
46. C McInnes A Mazumdar M Mezna C Meades C Midgley F Scaerou L Carpenter M Mackenzie P Taylor M Walkinshaw Inhibitors of polo-like kinase reveal roles in spindle-pole maintenance Nat Chem Biol 2 2006 608 617
47. C McInnes M Mezna PM Fischer Progress in the discovery of polo-like kinase inhibitors Curr Top Med Chem 5 2005 181 197
48. SJ Chiu G Marcucci RJ Lee Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes Anti-cancer Res 26 2006 1049 1056
49. RI Hogrefe AV Lebedev G Zon KF Pirollo A Rait Q Zhou W Yu EH Chang Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2 Nucleosides Nucleotides Nucleic Acids 25 2006 889 907
50. JH Jeong SH Kim SW Kim TG Park In vivo tumor targeting of ODN-PEG-folic acid/PEI polyelectrolyte complex micelles J Biomater Sci Polym Ed 16 2005 1409 1419